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InTroduCTIon
Neoadjuvant chemotherapy (NAC) is increasingly used 
in the treatment of primary breast cancer to downstage 
locally advanced disease and axillary nodal involvement 
prior to surgery and render breast conserving surgery and 
sentinel node biopsy feasible.1,2 It has been demonstrated 
that the response of the primary tumour to NAC correlates 
with patient survival3,4 and the amount of residual tumour 
left at surgical resection, as quantified by the residual 
cancer burden (RCB) score, is directly linked with patient 
outcomes.5,6 With modern chemotherapy regimens, patho-
logical complete response (pCR) to NAC is increasingly 
common. If patients who ultimately achieve a pCR could 
be confidently identified pre-operatively, they might not, in 
the future, require surgical intervention after NAC comple-
tion.7,8 For this reason, identification of relevant biomarkers 
of response are essential for improving and personalising 
patient management.
Several imaging modalities have been used to assess 
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objective: Does method of tumour volume measure-
ment on MRI influence prediction of treatment outcome 
in patients with primary breast cancer undergoing 
neoadjuvant chemotherapy (NAC)?.
Method: The study comprised of  136 women with 
biopsy-proven breast cancer scheduled for MRI moni-
toring during NAC treatment. Dynamic contrast- 
enhanced images were acquired at baseline (pre-NAC) 
and interim (post three NAC cycles) time points. Func-
tional tumour volumes (FTVs), automatically derived 
using vendor software and enhancing tumour volumes 
(ETVs), user-derived using a semi-automated thresh-
olding technique, were calculated at each time  point 
and percentage changes calculated. Response, assessed 
using residual cancer burden (RCB) score on surgically 
resected specimens, was compared statistically with 
volumetric changes and receiver operating character-
istic analysis performed.
results: Mean volumetric differences for each RCB 
response category were (FTV/ETV): pathological 
complete response (pCR) 95.5/96.8%, RCB-I 69.8/66.7%, 
RCB-II 64.0/65.5%, RCB-III 25.4/24.0%. Differences were 
significant between pCR and RCB-II/RCB-III catego-
ries (p  <  0.040; unpaired t-test) using FTV measures 
and between pCR and RCB-I/RCB-II/RCB-III catego-
ries (p  <  0.006; unpaired t-test) when ETV was used. 
Receiver operating characteristic analysis for pCR iden-
tification post-NAC yielded area under the curve for 
FTV/ETV of 0.834/0.920 respectively. Sensitivity and 
specificity for FTV was 80.0 and 76.8% for FTV and 81.0 
and 91.8% for ETV.
Conclusion: ETV changes can identify patients likely 
to achieve a complete response to NAC. Potentially, 
this could impact patient management regarding the 
possible avoidance of post-NAC surgery.
advances in Knowledge: Interim changes in ETV are 
more useful than FTV in predicting final pathological 
response to NAC. ETV differentiates patients who will 
achieve a complete response from those who will have 
residual disease. 
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shearwave elastography and MRI. Breast MRI, particularly 
dynamic contrast-enhanced imaging (DCE-MRI), appears to 
be more accurate than clinical examination, mammography or 
ultrasound in assessing final response to NAC.9,10 More recently, 
however, attention has focused on the correlation of early changes 
in breast MRI with pathological response. Various parameters 
have been investigated, including tumour size changes,11 diffu-
sion changes,12,13 contrast uptake and washout kinetics14,15 as 
well as more complex pharmacokinetic modelling parameters16 
and textural analysis.17–19
However, the ACRIN 6657 I-SPY TRIAL reported that the 
changes between baseline and interim MRI in a simpler metric, 
functional tumour volume (FTV), were the most useful in the 
early prediction of response.20,21 Furthermore, baseline tumour 
volume and changes in response to treatment carry important 
prognostic information, smaller reductions in volume being 
associated with poorer patient-related outcomes.11,22 The FTV 
reflects the number of pixels within a breast tumour that reach 
a minimum pre-defined threshold of signal enhancement early 
after contrast administration; all such pixels are summed to 
produce a volume. The enhancement threshold generally used is 
50% but it may be as high at 100%. Pixels that attain the threshold 
are usually also “coloured” to provide further information as 
to whether signal intensity reduces, plateaus, or continues to 
increase steadily after the peak enhancement, reflecting the pres-
ence or absence of contrast washout and thus, providing a visual 
summary of tumour enhancement kinetics (Figure 1). However, 
FTV measures require either dedicated computer-aided detec-
tion (CAD) software or MR vendor-specific post-processing 
programmes, and there is no clear evidence to indicate which 
enhancement threshold should be used. Standardised thresholds 
are likely to result in lesions with lower or slower enhancement 
being erroneously missed or measured as smaller than they actu-
ally are. Furthermore, thresholds are likely to vary from scanner 
to scanner due to different coil architectures and will be specific 
to a given set of imaging parameters and contrast agent.
A simpler measure of tumour volume is measurement of the total 
number of pixels that enhance around 2 min post contrast injec-
tion, denoted the enhancing tumour volume (ETV). The ETV 
can be measured without sophisticated computer software, using 
either commercial or freely available packages with operator-de-
fined thresholding methods. Such techniques, while potentially 
less reproducible, allow for user experience and interpretation to 
be taken into account and might go some way to obviate the issue 
of erroneous exclusion of viable tumour as a result of changed 
enhancement patterns in response to NAC.23
The aim of this study was to investigate whether changes in 
ETV or FTV between baseline and interim MRI are useful in 
predicting a pCR in patients undergoing NAC for primary breast 
cancer. As ETV is a user-interactive technique, the reproduc-
ibility of ETV was also measured.
MeThodS and MaTerIalS
Patients
This was a single-institution study performed on females with 
biopsy-proven primary breast cancer scheduled for NAC and 
Figure 1. (a) Pixels are colour coded after reaching a minimum enhancement threshold (Min %). They are then coloured according 
to whether there is persistent enhancement (+10%), plateau enhancement (± 10%) or washout enhancement (–10%). However, the 
technique does not take into account slower or lower enhancing pixels as shown.as shown. (b) Example image of how pixels are 
coloured and the corresponding calculated functional tumour volume, considered in terms of washout, plateau and persistent 
enhancement as shown in (a).
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referred for MRI examinations for treatment monitoring. All 
females gave written consent for images to be used for research 
purposes and ethical approval was waived for this anonymised, 
retrospective study.
From 172 consecutively scanned patients, a total of 36 patients 
were excluded from the study due to excessive motion (n = 18), 
poor image quality due to fat saturation failure (n = 9), incor-
rect timing of MRI examinations relative to NAC treatment 
(n = 4), failure to complete NAC prior to surgery (n = 2), no final 
pathology available (n = 2) or non-standard management (n = 
1). The remaining 136 patients comprised the study cohort, who 
underwent MRI examinations at baseline (prior to NAC) and at 
interim (after 2 or 3 cycles of NAC).
In these 136 patients, 40 cancers were oestrogen receptor posi-
tive (ER+, Allred score ≥3) and HER2 negative; 9 were HER2+ 
(immunohistochemistry 3 or 2 + with fluorescence in situ hybri-
disation amplified) and ER-; and 50 were classified as triple 
negative breast cancer (Allred score <3 and HER2 0, 1 or 2 + 
with fluorescence in situ hybridisation non-amplified). There 
was also a hybrid group (both ER and HER2 positive) of 37 
patients.
28 patients received six cycles of FEC (fluorouracil, epirubicin 
and cyclophsphamide); 62 female, three cycles of FEC followed 
by three cycles of docetaxel. All patients with HER2 positive 
disease underwent three cycles of FEC and either three cycles of 
docetaxel and trastuzumab (n = 41) or docetaxel with trastuzum-
ab-emtansine (TDM1) (n = 5).
MRI examination
Patients were scanned prior to NAC and after NAC cycle 2 (n = 
22) or cycle 3 (n = 114). At interim MRI examination, all patients 
had received only FEC treatment.
All MRI examinations were performed on a 32-channel 3.0  T 
Siemens Magnetom Trio or Siemens PrismaFIT (Erlangen, 
Germany) MRI scanner using a dedicated bilateral breast coil. 
The imaging protocol consisted of standard anatomical imaging 
(T2 weighted turbo spin echo, diffusion-weighted imaging and 
a high resolution T1  weighted post-contrast sequence). The 
DCE-MRI sequence was performed using a three-dimensional 
spoiled gradient echo volumetric sequence (FLASH) with fat 
suppression (repetition time/echo time/α = 3.4 ms/1.22 ms/6°, 
voxel size = 0.8 × 0.8 × 0.8 mm3, parallel imaging factor × 2). 
The complete dynamic acquisition consisted of eight volu-
metric acquisitions (each of 49–58 s), with contrast injected at 
the end of the second volume acquisition. All patients received 
a 0.1 mmol kg−1 dose of Dotarem (Guerbet , France), injected at 
2.0 ml s−1, followed by 20 ml saline flush, using a power injector 
(Spectris Solaris EP; Medrad, Pittsburgh, PA).
Image analysis
All volumetric measurements were performed blinded to patient 
outcome, clinical information and final pathology. In patients 
with multifocal disease, only the largest lesion was analysed for 
each scan. All patients had only unilateral disease.
FTV was measured using a fully automated breast CAD package 
(SyngoVia BreVis; Siemens, Erlangen,  Germany) with a stan-
dardised threshold value of 50% at 2 min post-contrast injection 
(as per manufacturers default setting). Pixels were coloured on 
the basis of whether enhancement was deemed to be washout 
(decrease in signal intensity of more than 10%), plateau (signal 
intensity that remained within ± 10%) or persistent (signal inten-
sity increase by more than 10%) relative to the peak enhance-
ment. Volumes of interest were drawn around regions of 
enhancement for pixel counting of those that met enhancement 
criteria (Figure 2).
ETV measurements were measured offline using a stand-alone 
PC. The 2 min post-contrast subtraction series Digital Imaging 
and Communications in Medicine images were exported onto 
this workstation and analysis was performed using a semi-au-
tomated threshold method in ITK-Snap software.24 Threshold 
and smoothing values were user-defined on a case-by-case basis 
using observer experience and clinical knowledge to match the 
thresholding mask to the enhancement on the 2 min post-con-
trast image (Figure 3). No standardised thresholds were used for 
this technique. Where there was evidence of linear non-mass 
enhancement extending from sold mass lesions, which was 
suspicious of ductal carcinoma in situ, this was also included 
within the measured volume. Measuring the ETV at baseline and 
interim look approximately 7 min per patient.
Due to the interactive nature of the volumetric calculation, intra- 
and interobserver repeatability was calculated for ETV measures. 
All data was analysed twice by SAH with a 1-month time interval 
between analysis sessions, and a subset of 100 patients was also 
analysed by NMG/SV.
Figure 2. Functional tumour volume calculation using Siemens 
BreVis software. All coloured pixels have reached minimum 
enhancement percentage of 50% and are assigned a colour 
based on whether time–intensity curve demonstrates wash-
out (red), plateau (green) or persistent (blue) enhancement. 
A region of interest placed over the region will count pixels to 
determine functional tumour volume.
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Assessment of response
Pathological response was assessed by a specialist breast 
pathologist (CAP) on the resected specimen, based on tumour 
bed dimensions, cellularity and axillary node burden as 
outlined by Symmans et al.5 The RCB was calculated and the 
variable dichotomised into an index, defining whether patients 
achieved a pCR, or had minimal (RCB-I), moderate (RCB-II) 
or marked (RCB-III) residual disease post-treatment. These 
RCB groups correspond with the risk of distant relapse-free 
survival.5
Statistics
Intra- and interobserver repeatability was assessed using a 








n− 1  
 (1)
Where m1,2 are the first and second measures made and n is the 
number of patients in the cohort.
As it was the change in volume that we were interested in, 
percentage volume reductions between baseline and interim 
MRI examinations were calculated for ETV and FTV measures 
for every patient, and these were compared with the ultimate 
pathological response, as measured using the RCB score.
A one-way ANOVA was performed to determine if there were 
any significant differences across all response groups for the base-
line volumes, as measured using either ETV or FTV, to ensure no 
bias to the final results. Baseline volumes for each immunophe-
notype were also tested for any relationship with ultimate patho-
logical response, using a Mann–Whitney U test. Correlation 
between the two volumetric assessment methods was assessed 
using a Pearson’s correlation coefficient, to ascertain consistency 
of measures between each method.
Unpaired t-tests were used for comparisons between the indi-
vidual response categories, and receiver operating characteristic 
curves (ROC) were generated using R Studio (v. 1.0143, www. 
R- project. org). The area under the ROC curves was calculated 
(AUROC) and optimal thresholds to identify pCR post-NAC 
treatment were derived using Youden’s index. Sensitivity, speci-
ficity, accuracy and positive and negative predictive values (PPV 
and NPV) were calculated based on these optimal thresholds.
reSulTS
Patient cohort
Within the cohort of 136 patients, there were a total of 151 lesions 
identified, however, the volumetric analysis was restricted to the 
largest, index lesion in each patient. Of these lesions, 109 were 
masses and there were 27 non-mass lesions. At final pathological 
examination, 24 patients were categorised as pCR, 20 as RCB-I, 
Figure 3. Enhancing tumour volume calculation using ITK-SNAP software. Only enhancing pixels are included in the volumetric 
measurement. User-thresholding is used to define the minimum intensity to include within the volume of interest.
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64 as RCB-II and 28 as RCB-III. When broken down into immu-
nohistochemical subtype, there were 40 ER + cancers (pCR: 7, 
RCB-I: 6, RCB-II: 22, RCB-III: 5), 9 HER2 + cancers (pCR: 2, 
RCB-I: 1, RCB-II: 2, RCB-III: 4), 37 hybrid cancers (pCR: 8, 
RCB-I: 5, RCB-II: 13, RCB-III: 11) and 50 triple negative cancers 
(pCR: 7, RCB-I: 8, RCB-II: 27, RCB-III: 8).
Reproducibility of ETV measurements
Intraobserver repeatability was calculated to be 2.7 cm3, with the 
average lesion volume 10.5 cm3. The interobserver repeatability 
coefficient was higher at 4.7 cm3 with average lesion volume size 
of 11.7 cm3. Bland–Altman plots are shown in Figure 4.
RCB response
There were no significant differences across all response catego-
ries for the baseline (presenting) tumour volume as measured 
using FTV (p = 0.642, one-way ANOVA) or ETV (p = 0.149, 
one-way ANOVA). Neither were there any significant differ-
ences across response categories when considered in terms of 
immunophenotypes (p > 0.429, one-way ANOVA).
In terms of immunophenotype, in the ER +  lesions there was 
a significant difference between the baseline (presenting) ETVs 
for patients who ultimately achieved a pCR compared with 
those with residual disease (RCB-I, II or III) (p = 0.028; Mann–
Whitney U test). There was no significant difference in the FTV 
(p = 0.191; Mann–Whitney U test), or in any measure of tumour 
volume for the HER2 + or hybrid lesions (p > 0.85).
As expected, there was a significant correlation between the FTV 
and the ETV measurements with a Pearson's correlation coeffi-
cient of 0.689 (p < 0.001).
Average and standard deviation percentage volume reductions 
are shown for both FTV and ETV techniques in Table  1 and 
Figure  5, for each response category. Patients who achieved a 
pCR had the greatest percentage reduction in tumour volume 
using both techniques, while those who had extensive residual 
disease at final pathology had the lowest percentage reduction in 
tumour volume.
Pairwise statistical comparisons demonstrate that for FTV 
measurement, there are significant differences between pCR and 
RCB-II and RCB-III categories (p < 0.040, unpaired t-test), but 
not between the pCR and RCB-I categories (p = 0.156, unpaired 
t-test). Significant differences were demonstrated for all RCB-I, 
RCB-II and RCB-III comparisons (p < 0.017, unpaired t-test).
For ETV, there were significant differences between pCR and 
all other categories (p < 0.006, unpaired t-test). There were 
significant differences in all other comparisons of categories, 
with the exception of RCB-I and RCB-II responders (p = 0.829, 
unpaired t-test). Notably for ETV, pCR demonstrates a signifi-
cantly distinct volumetric change between baseline and interim 
MRI relative to all patients who had some form of residual 
disease.
Figure 4. Bland–Altman plots of intraobserver (top) and inter-
observer (bottom) repeatability. ETV, enhancing tumour vol-
ume; FTV, functional tumour volume.
Table 1. Average reductions in volume for both volumetric measurement methods in each pathological response category
FTV ETV 
Average volume reduction Standard deviation Average volume reduction Standard deviation 
pCR 95.2 % 23.8 % 96.8 % 11.1 % 
RCB-I 69.8 % 23.6 % 66.7 % 41.9 % 
RCB-II 64.0 % 35.2 % 65.5 % 34.3 % 
RCB-III 25.4 % 39.4 % 24.0 % 35.7 % 
ETV, enhancing tumour volume; FTV, functional tumour volume; pCR, pathological complete response.
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When considered in terms of immunohistochemical subtype, 
significance between pCR and RCB-I categories were lost for 
ETV measures (p > 0.051, unpaired t-test), and for both ETV and 
FTV, there were no significant differences in any metric between 
RCB-I and RCB-II (p > 0.081, unpaired t-test).
ROC analysis was used to compare the prediction of pCR after 
treatment using both FTV and ETV volumetric changes between 
baseline and interim MRI. The resulting AUC was good for FTV 
(AUROC = 0.834) and excellent for ETV (AUROC = 0.920), 
however, there were no significant differences between the 
curves (p = 0.233), as shown in Figure 6.
Using Youden’s index, optimal thresholds for pCR prediction 
were derived. For FTV, a 75.6% reduction resulted in a sensitivity 
and specificity of 80.0 and 76.8% respectively, while a reduction 
of 89.8% in ETV measure gave a sensitivity and specificity of 81.0 
and 91.8%. Full diagnostic performance is presented in Table 2, 
which demonstrates the superior rates for ETV measures.
dISCuSSIon
NAC is increasingly used in breast cancer management, and 
females with a pCR have improved overall survival.25–27 Image 
analysis has the potential to assess response during therapy, prior 
to surgical resection, however, there is still lack of any consensus 
as to the best metric that correlates with ultimate pathological 
outcome.
We have demonstrated that changes in ETV between baseline 
and interim MRI may provide a more accurate predictive assess-
ment of pCR to NAC compared with FTV. ROC curves demon-
strate no statistically significant differences between the two 
methods, however, there are improved diagnostic performance 
criteria for the ETV method compared with a comparable assess-
ment of FTV changes.
Figure 5. Percentage volume reduction for each response cat-
egory for FTV (upper graph) and ETV (lower graph). Signif-
icant differences between response categories are indicated 
(p < 0.05; unpaired t-test).  ETV,  enhancing tumour volume; 
FTV, functional tumour volume; pCR, pathological complete-
response.
Figure 6. ROC curves demonstrating sensitivity and specific-
ity in prediction of pCR after treatment based on volumetric 
changes measured between baseline and interim MRI using 
FTV and ETV methods. ETV, enhancing tumour volume; FTV, 
functional tumour volume; ROC. receiver operating character-
istic.
Table 2. Diagnostic performance criteria in the prediction of 
pCR post-NAC treatment when using volumetric changes 







Sensitivity 80.0% 81.0% 
Specificity 76.8% 91.8% 
Accuracy 77.4% 89.8% 
PPV 42.1% 68.0% 
NPV 77.4% 95.7% 
ETV, enhancing tumour volume; FTV, functionaltumour volume; NPV, 
positive-predictive value; PPV, negative-predictive value.
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Due to the user-thresholding of the ETV method, reproduc-
ibility assessment was performed, which resulted in average 
reproducibility for intraobserver repeatability, but only 
moderate reproducibility for interobserver measures. It should 
be noted, however, that while one observer had a number of 
years of experience in using the software, the other observer 
had very limited experience; therefore it is likely that the 
gap in intra- and interobserver variability could be reduced 
substantially. Although some training in the use of ITK-SNAP 
is required, it is easy to use, freely available and once familiar 
with the functions, segmentation can be carried out quickly, 
typically taking a few minutes per data set. On the other hand, 
a fully automated method would potentially be more useful in 
the clinical arena once fully validated. Non-mass enhancement 
was significantly more subjective to measure, and generally 
required a greater degree of interpretation and experience in 
defining the extent of enhancement. While only inclusion of 
solid mass lesions would likely have increased the reproduc-
ibility of the ETV technique, it would be unlikely to reflect true 
tumour burden.
No standardised thresholds were utilised in ETV measurements, 
as this would then limit the technique to the drawbacks asso-
ciated with FTV measurement—i.e. slowly or lesser enhancing 
tumours would be underestimated. The semi-automated tech-
nique of utilising ETV means that a degree of observer judge-
ment based on experience can be combined by increasing or 
decreasing thresholds to accurately include the regions of suspi-
cious enhancement, e.g. in inclusion of linear enhancement 
reflecting ductal carcinoma in situ that generally enhances to a 
lesser degree than mass lesions. It should also be noted that it 
has previously been reported that different tumour immunophe-
notypes require different enhancement thresholds due to differ-
ences in enhancement patterns,28 reflecting our findings here 
that a user-interactive technique is likely to be more accurate in 
describing tumour volumes.
Reports suggest that FTV can be used to predict not only pCR 
to NAC, but also recurrence-free survival.20,21 However, it has 
also been reported that the thresholds used for FTV calcula-
tion have a significant impact on the measured volumes29–31 
and thresholds also are dependent on the breast cancer immu-
nohistochemical subtype.28 It has been shown that taxanes have 
an anti-angiogenic effect and hence, may result in diminished 
enhancement when there is in fact residual disease,23 meaning 
that automated methods have the potential to underestimate the 
amount of disease present. On the other hand, use of an inter-
active thresholding technique enables an experienced reader 
to compensate for this, which may explain in part the superior 
differentiation between ultimate pCR and RCB-I groups. There 
are also differences in the way that different software platforms 
implement the FTV measure31 and such measures are dependent 
on good quality dynamic data, so poor fat saturation and motion 
can result in incorrect or even failure of calculation,31 which is 
not an issue for ETV measures as they are used on a standalone 
image. By contrast, with user-defined interactive platforms, there 
is the possibility of compensating for misregistration and poor 
fat suppression.
There have been numerous studies that have reported the 
utility of tumour volume, and the importance of this param-
eter importance in prediction of NAC outcome.11,32–34 
Tumour volume has been reported to be more indicative of 
ultimate outcome to treatment than other simpler measures 
such as tumour diameter,11,21 diffusion-weighted parameters33 
and more complex pharmacokinetic modelling parameters.34 
In fact, the I-SPY trial concluded that FTV performed better 
than maximum diameter measurements at predicting ultimate 
outcome at all time points—early, interim and post-treat-
ment imaging examinations.21 As FTV measures are readily 
available on all commercial breast CAD packages, which 
are recommended for use in reporting breast MRI exam-
inations, it is therefore, a more appropriate metric to use in 
clinical reporting than tumour diameter measurements. 
However, to date, there have been no direct comparisons of 
the two volumetric measures considered in this study—FTV 
and ETV.
As FTV measures are dependent entirely on enhancement 
thresholds, in turn this will result in a likely dependence on 
factors affecting signal to noise ratio such as field strength, coil 
architecture as well as imaging parameters, which to our knowl-
edge has not been investigated within the literature and requires 
clarification prior to implementation as a clinical prediction tool. 
While ETV requires transfer of data offline, it is less likely to be 
prone to such factors and potentially will provide a more robust 
measurement tool.
The ability to confidently predict a pCR to NAC on imaging 
assessment alone could potentially facilitate novel approaches 
to surgical management, e.g. only performing percutaneous 
sampling of the tumour bed and radiotherapy treatment and 
dispensing with surgical intervention.7,8 Such feasibility studies 
are indeed already underway in the USA and the UK and are a 
step towards personalised treatment.
When considering subtypes of breast cancer, similar trends 
were observed, however, these were not significant between 
pCR and RCB-I responders, most likely due to the smaller 
numbers in each comparative groups. The ETV pCR  vs  RCB-I 
comparison for hybrid cancers was approaching significance 
(p = 0.051, unpaired t-test) with 37 patients, and therefore, 
warrants further investigation in larger cohorts. Unfortu-
nately, it was not possible to perform response assessment in 
the ER-HER2 + group as there were only nine patients in this 
cohort. While the reported rates within the literature for pCR 
may appear higher, it should be noted that there is a discrep-
ancy in the use of the term “pCR” within the literature, with 
some groups reporting pCR as no evidence of invasive cancer 
or in situ disease in the breast or nodes, no evidence of invasive 
cancer in the breast or nodes (irrespective of in situ disease) or 
no evidence of invasive cancer in the breast (irrespective of in 
situ disease or nodal involvement).
We considered only baseline and interim MRI examinations in 
this study, in line with previous findings from the I-SPY trial that 
changes in FTV between baseline and interim MRI were better 
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